If you have been reading about AOD9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-07. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Jackson-Pratt drain – consists of a perforated round or flat tube connected to a negative pressure collection device. The collection device is typically a bulb with a drainage port which can be opened to remove fluid or air. After compressing the bulb to remove fluid or air, negative pressure is created as the bulb returns to its normal shape. Blake drain – a round silicone tube with channels that carry fluid to a negative pressure collection device. Drainage is thought to be achieved by capillary action, allowing fluid to travel through the open grooves into a closed cross section, which contains the fluid and allows it to be suctioned through the tube. Penrose drain – a soft rubber tube. Negative pressure wound therapy – Involves the use of enclosed foam and a suction device attached; this is one of the newer types of wound healing/drain devices which promotes faster tissue granulation, often used for large surgical/trauma/non-healing wounds. Redivac drain – a high negative pressure drain. Suction is applied through the drain to generate a vacuum and draw fluids into a bottle. Shirley drain. Chest tube – is a flexible plastic tube that is inserted through the chest wall and into the pleural space or mediastinum.
This looked like a declaration of war against the Catholic and monarchist majority in the Legislative Assembly, which had been elected on 28 May in a moment of panic. But the president again pretended to be playing the game of the Orléanists, as he had done in the case of the Constituent Assembly. The complementary elections of March and April 1850 resulted in an unexpected victory for the republicans which alarmed the conservative leaders, Thiers, Berryer and Montalembert. The president and the Assembly co-operated in the passage of the Loi Falloux of 15 March 1850, which again placed university instruction under the direction of the Church. A conservative electoral law was passed on 31 May. It required each voter to prove three years' residence at his current address by way of entries in the record of direct taxes. This effectively repealed universal suffrage: factory workers, who moved fairly often, were thus disenfranchised. The law of 16 July aggravated the severity of the press restrictions by re-establishing the "caution money" (cautionnement) deposited by proprietors and editors of papers with the government as a guarantee of good behaviour. Finally, an interpretation of the law on clubs and political societies suppressed about this time all the republican societies.
25 April Downing Street confirms the first UK evacuation flight carrying British citizens has left Sudan. High Court documents reveal that Prince William was paid a "very large sum" by News Group Newspapers, owners of The Sun, to settle historical phone-hacking claims. Data published by the Office for National Statistics indicates government borrowing for the year up to 31 March 2023 to be £139.2bn, less than the £152bn that had been forecast by the Office for Budget Responsibility prior to the 2023 budget. 26 April Andrew Bridgen is expelled from the Conservative Party after comparing COVID-19 vaccines to the Holocaust and being found to have breached lobbying rules. The first evacuation flight from Sudan lands in the UK. The Illegal Migration Bill passes its final stage in the House of Commons, with MPs voting 289–230 in favour of the bill. The UK's Competition and Markets Authority blocks Microsoft's £55bn deal to buy US video game company Activision Blizzard, citing concerns about reduced choice for gamers and reduced innovation; the move needed the approval of competition regulators in the United States, United Kingdom and European Union. 27 April Three days of fresh train strikes are called after both ASLEF and the RMT reject a pay offer from the Rail Delivery Group. The strikes dates are announced for 13 May 31 May and 3 June (ASLEF) and 13 May (RMT).
Formylglycine-generating enzyme (FGE), located at 3p26.1 in humans, is the name for an enzyme present in the endoplasmic reticulum that catalyzes the conversion of cysteine to formylglycine (fGly). There are two main classes of FGE, aerobic and anaerobic. FGE activates sulfatases, which are essential for the degradation of sulfate esters. The catalytic activity of sulfatases is dependent upon a formylglycine (sometimes called oxoalanine) residue in the active site.
Sources: en.wikipedia.org
== Modern experimental pathology == As new research techniques, such as electron microscopy, immunohistochemistry, and molecular biology have expanded the means by which biomedical scientists can study disease, the definition and boundaries of investigative pathology have become less distinct. In the broadest sense, nearly all research which links manifestations of disease to identifiable processes in cells, tissues, or organs can be considered experimental pathology.
== Directed panspermia == During the 1960s, Crick became concerned with the origins of the genetic code. In 1966, Crick took the place of Leslie Orgel at a meeting where Orgel was to talk about the origin of life. Crick speculated about possible stages by which an initially simple code with a few amino acid types might have evolved into the more complex code used by existing organisms. At that time, proteins were thought to be the only kind of enzyme, and ribozymes had not yet been identified. Many molecular biologists were puzzled by the problem of the origin of a protein replicating system that is as complex as that which exists in organisms currently inhabiting Earth. In the early 1970s, Crick and Orgel further speculated about the possibility that the production of living systems from molecules may have been a very rare event in the universe, but once it had developed it could be spread by intelligent life forms using space travel technology, a process they called "directed panspermia". In a retrospective article, Crick and Orgel noted that they had been unduly pessimistic about the chances of abiogenesis on Earth when they had assumed that some kind of self-replicating protein system was the molecular origin of life. In 1976, Crick addressed the origin of protein synthesis in a paper with Sydney Brenner, Aaron Klug, and George Pieczenik. In this paper, they speculate that code constraints on nucleotide sequences allow protein synthesis without the need for a ribosome.
== Release == Lost Coast was released on October 27, 2005, as a free download for owners of Half-Life 2 on Steam. Valve announced on May 30, 2007, that Lost Coast, along with Half-Life 2: Deathmatch, would be made available for free to owners of ATI Radeon cards. It was later released without charge to Nvidia graphics card owners along with Half-Life 2: Deathmatch, Peggle Extreme, and the first eleven levels of Portal. In 2024, the 20th anniversary of Half-Life 2, Valve updated Half-Life 2 to incorporate Lost Coast and other features.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.